综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Americas

US FDA issues emergency use authorization for first COVID-19 vaccine

Xinhua | Updated: 2020-12-12 14:08
Share
Share - WeChat
In this file photo illustration taken on Nov 23, 2020, shows a syringe and a bottle reading "COVID-19 Vaccine" next to the Pfizer company logo. [Photo/Agencies]

WASHINGTON -- The US Food and Drug Administration (FDA) Friday issued authorization for emergency use of the first COVID-19 vaccine in the United States.

The first Emergency Use Authorization (EUA) was issued to the COVID-19 vaccine of American drugmaker Pfizer in partnership with German company BioNTech, allowing the vaccine to be distributed in the United States.

The FDA has determined that Pfizer-BioNTech COVID-19 vaccine has met the statutory criteria for issuance of an EUA. The totality of the available data provides clear evidence that Pfizer-BioNTech COVID-19 vaccine may be effective in preventing COVID-19, said the FDA in a statement.

The data also show that the known and potential benefits outweigh the known and potential risks, supporting the vaccine's use in millions of people 16 years of age and older, said the FDA.

"The FDA's authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world," said FDA Commissioner Stephen Hahn.

"Today's action follows an open and transparent review process that included input from independent scientific and public health experts and a thorough evaluation by the agency's career scientists to ensure this vaccine met FDA's rigorous, scientific standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization," he said in a statement.

The Pfizer-BioNTech vaccine contains a small piece of the SARS-CoV-2 virus's mRNA that instructs cells in the body to make the virus's distinctive "spike" protein.

When a person receives this vaccine, their body produces copies of the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against SARS-CoV-2.

The vaccine is administered as a series of two doses, three weeks apart.

Global COVID-19 cases surpassed 70 million on Friday, according to the Center for Systems Science and Engineering at Johns Hopkins University. The United States reported the most cases and deaths around the world as of 4:28 pm local time (2128 GMT), numbering 15,758,661 and 293,785, respectively.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
论坛| 柳州市| 铅山县| 廊坊市| 明光市| 永兴县| 民权县| 忻州市| 赤壁市| 葫芦岛市| 南投县| 洛南县| 深泽县| 江油市| 紫云| 黎城县| 金昌市| 昌都县| 资中县| 汕尾市| 丰县| 贵南县| 西乌珠穆沁旗| 临高县| 延吉市| 三河市| 云南省| 双柏县| 临漳县| 宿松县| 遵义市| 和田县| 呼玛县| 兴业县| 天全县| 比如县| 武城县| 高陵县| 咸宁市| 上栗县| 澄城县|